RB1-mutant lung cancer cells tended to be sensitive to olaparib, niraparib, and talazoparib in the Genomics of Drug Sensitivity in Cancer (GDSC) and the Cancer Therapeutics Response Portal (CTRP) data sets (Figure 1, B–J). Here, RB1 is linked to lung cancer.